Triapine 联合化疗和放疗治疗 IB2-IVA 宫颈癌或阴道癌患者
口服 triapine 联合同步放化疗治疗局部晚期宫颈癌 (LACC) 和阴道癌的 I 期剂量递增生物利用度研究
This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer. Triapine may stop the growth of cancer cells by blocking an enzyme needed for cell growth. Cisplatin is a drug used in chemotherapy that kills cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Adding triapine to standard treatment with cisplatin and radiation therapy may kill more cancer cells.
研究概览
地位
条件
干预/治疗
- 药品:Cisplatin
- 程序:Magnetic Resonance Imaging
- 其他:Pharmacological Study
- 程序:Biospecimen Collection
- 辐射:Intensity-Modulated Radiation Therapy
- 程序:Computed Tomography
- 程序:Positron Emission Tomography
- 辐射:Brachytherapy
- 辐射:External Beam Radiation Therapy
- 其他:Fludeoxyglucose F-18
- 辐射:High-Dose Rate Brachytherapy
- 药品:Triapine
详细说明
PRIMARY OBJECTIVES:
I. To determine the maximum tolerable dose (MTD) and recommended phase II dose (RP2D) of oral triapine when used in combination with cisplatin plus radiation therapy.
II. To determine the oral bioavailability of triapine. III. To describe the pharmacokinetics (PK) of oral and intravenous triapine.
SECONDARY OBJECTIVES:
I. To determine whether the metabolic complete response (mCR) rate of oral triapine in combination with cisplatin chemoradiation using fludeoxyglucose F 18 (18F-FDG)-positron emission tomography (PET)/computed tomography (CT) at post-therapy (3-month) is at least 70%.
II. To determine clinical overall response rate, progression-free survival, and overall survival.
III. To determine the correlation of methemoglobin proportion (%) and triapine pharmacokinetic exposure.
EXPLORATORY OBJECTIVE:
I. To determine whether active human immunodeficiency virus (HIV) antiretroviral therapy impacts the antitumor activity of triapine.
OUTLINE: This is a dose-escalation study of triapine.
Patients undergo pelvic external beam radiation therapy (EBRT) or intensity modulated radiation therapy (IMRT) 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of low dose rate (LDR) brachytherapy in week 6 or 5 fractions of high dose rate (HDR) brachytherapy at week 4 or 5. Patients also receive triapine intravenously (IV) over 120 minutes on day 1 and orally (PO) on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo magnetic resonance imaging (MRI) and FDG-PET/CT during follow-up.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- University of Alabama at Birmingham Cancer Center
-
-
California
-
Los Angeles、California、美国、90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles、California、美国、90033
- Los Angeles General Medical Center
-
Pasadena、California、美国、91105
- Keck Medical Center of USC Pasadena
-
-
Kansas
-
Fairway、Kansas、美国、66205
- University of Kansas Clinical Research Center
-
Kansas City、Kansas、美国、66160
- University of Kansas Cancer Center
-
Overland Park、Kansas、美国、66211
- University of Kansas Hospital-Indian Creek Campus
-
Westwood、Kansas、美国、66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- University of Kentucky/Markey Cancer Center
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- University of Michigan Rogel Cancer Center
-
Detroit、Michigan、美国、48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills、Michigan、美国、48334
- Weisberg Cancer Treatment Center
-
-
New Jersey
-
New Brunswick、New Jersey、美国、08903
- Rutgers Cancer Institute of New Jersey
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15232
- UPMC Hillman Cancer Center
-
-
Virginia
-
Charlottesville、Virginia、美国、22908
- University of Virginia Cancer Center
-
Richmond、Virginia、美国、23298
- VCU Massey Comprehensive Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patient has a new, untreated histologic diagnosis of stage IB2 (> 5 cm), II, IIIB, IIIC or IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix or stage II-IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the vagina not amenable to curative surgical resection alone; the presence or absence of lymph node metastasis will be based on pre-therapy 18F-FDG PET/CT; the patient must be able to tolerate imaging requirements of an 18F-FDG PET/CT scan
-
Age >= 18 years old
-
Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
-
Life expectancy greater than 6 months
-
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
-
Platelets >= 100 x 10^9/L
-
Hemoglobin (Hgb) >= 10.0 g/dL (blood transfusions to reach this amount are allowed)
-
Serum creatinine =< 1.5 mg/dL to receive weekly cisplatin
- If serum creatinine is between 1.5 and 1.9 mg/dL, patients are eligible for cisplatin if the estimated creatinine clearance (CCr) is > 30 ml/min (for the purpose of estimating the CCr, the formula of Cockcroft and Gault for females should be used)
-
Total serum bilirubin =< 1.5 x upper limit of normal (ULN) (in patients with known Gilbert syndrome, a total bilirubin =< 3.0 x ULN, with direct bilirubin =< 1.5 x ULN)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
-
Able to take oral medication
-
Not pregnant and not breastfeeding; the effects of triapine on the developing human fetus are unknown; for this reason as well as because heterocyclic carboxaldehydethiosemicarbazones and radiation are known to be teratogenic, women of child-bearing potential and men must agree to use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; patient must have documented negative urine pregnancy test must be resulted within 7 days before initiating protocol therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with triapine, breastfeeding should be discontinued if the mother is treated with triapine; these potential risks may also apply to other agents used in this study
-
For HIV and hepatitis B/C (HEPB/C):
- HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for the dose escalation portion of this trial; for those patients who are enrolled in the HIV positive (+) expansion cohort, they must be HIV infected and be on retroviral therapy with an undetectable viral load within 6 months of enrollment
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured; for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Able to understand and willingness to sign a written informed consent document
Exclusion Criteria:
- Patient has had a prior invasive malignancy diagnosed within the last three years (except [1] non-melanoma skin cancer or [2] prior in situ carcinoma of the cervix)
- Patients are excluded if they have received prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physician
- Patients receiving any other investigational agents
- Patients with known glucose-6-phosphate dehydrogenase deficiency (G6PD) are excluded due to an inability to administer the antidote for methemoglobinemia, methylene blue; pre-registration testing for G6PD is at the investigator's discretion and is not required for study enrollment
- Patients who are taking any medication associated with methemoglobinemia; medication must be discontinued and must have a washout period of 4 halflives or 4 weeks, whichever is shorter
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatin
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; known inadequately controlled hypertension; significant pulmonary disease including dyspnea at rest, patients requiring supplemental oxygen, or poor pulmonary reserve; or psychiatric illness/social situations that would limit compliance with study requirements
- Patients with uncontrolled diabetes mellitus (fasting blood glucose controlled by medication, =< 200 mg/dL allowed)
- Patients who have had a hysterectomy or are planning to have an adjuvant hysterectomy following radiation as part of their cervical cancer treatment are ineligible
- Patients scheduled to be treated with adjuvant consolidation chemotherapy at the conclusion of their standard chemoradiation
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment (triapine, chemoradiation)
Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up. |
Given IV
其他名称:
Undergo MRI
其他名称:
Correlative studies Undergo collection of blood samples
其他名称:
Undergo IMRT
其他名称:
Undergo FDG-PET/CT
其他名称:
Undergo FDG-PET/CT
其他名称:
Undergo LDR brachytherapy
其他名称:
Undergo pelvic EBRT
其他名称:
Undergo FDG-PET/CT
其他名称:
Undergo HDR brachytherapy
其他名称:
Given IV and PO
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
消除半衰期 (t 1/2)
大体时间:给药后 24 小时内
|
给药后 24 小时内
|
|
|
Maximum Tolerated Dose (MTD)
大体时间:Up to 5 weeks
|
The MTD was determined following a standard 3+3 design is as follows: Escalation at 0/3 DLTs, dose-reduction if >1/3 DLT, and expansion to 6 if 1/3 DLTs. DLT is defined as the severe toxicity event that leads to the termination of the treatment as defined in section 5.5. The highest dose level where <2/6 DLTs are observed will be declared MTD |
Up to 5 weeks
|
|
Number of Patients Who Experienced a DLT
大体时间:Up to 5 weeks
|
Number of patients that experienced a DLT, evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. DLTs are defined as the following adverse events if considered at least "possibly related" to a component of the study therapy and which occur from the start of treatment until completion of EBRT, prior to initiation of brachytherapy (i.e. the first 5 weeks if no treatments are missed): Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 3 toxicity not resolved with maximal intervention to Grade 0-2 over 7 days (except alopecia and fatigue); Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 4 toxicity; Any other non-hematologic toxicity ≥Grade 3; Any hematologic toxicity of ≥ Grade 4; Grade ≥3 dyspnea; Inability to deliver at least 20 of the scheduled 25 administrations of triapine at the planned dose, allowing for 2 weeks to make up missed radiation days. Inability to deliver |
Up to 5 weeks
|
|
Bioavailability of Triapine
大体时间:Up to 2 weeks
|
The oral bioavailability of the oral form of the triapine will be measured as a numeric value using mass spectrophotometry. |
Up to 2 weeks
|
|
Cmax
大体时间:Up to 24 hours after dosing
|
Maximum concentration |
Up to 24 hours after dosing
|
|
Tmax
大体时间:Up to 24 hours after dosing
|
Time to maximum concentration, |
Up to 24 hours after dosing
|
|
AUC
大体时间:Up to 24 hours after dosing
|
Area Under the Concentration-Time Curve (AUC 0-last) |
Up to 24 hours after dosing
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Fludeoxyglucose F18-Positron Emission Tomography Computed Tomography Metabolic Complete Response (mCR) Rate
大体时间:At 3 months post-treatment
|
The mCR rate at recommended phase 2 dose, defined as a metabolic complete response on PET/CT will be defined as greater than -66% reduction in tumor FDG uptake at sites of abnormal tumor FDG uptake noted on pre-treatment FDG-PET study (considering normal cardiac or liver blood pool). |
At 3 months post-treatment
|
|
Clinical Overall Response Rate
大体时间:3 months post-treatment
|
Clinical response at the recommended phase 2 dose per RECIST v1.1 Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
3 months post-treatment
|
|
Progression Free Survival (PFS)
大体时间:Up to 4 years and 2 months from start of treatment
|
Median number of months that patients survive without disease progression from end of treatment. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 4 years and 2 months from start of treatment
|
|
Overall Survival (OS)
大体时间:Up to 4 years and 2 months from start of treatment
|
Median number of months that patients remain alive after end of treatment. |
Up to 4 years and 2 months from start of treatment
|
合作者和调查者
调查人员
- 首席研究员:Sarah E Taylor、University of Pittsburgh Cancer Institute LAO
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 生殖器疾病
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 子宫疾病
- 生殖器疾病,女性
- 生殖器肿瘤,女性
- 宫颈疾病
- 子宫肿瘤
- 宫颈肿瘤
- 调查技术
- 疗法
- 临床实验室技术
- 诊断技术和程序
- 诊断
- 碳水化合物
- 身体现象
- 无机化学物质
- 氯化合物
- 氮化合物
- 元素
- 金属
- 组织
- 卫生保健经济学和组织
- 化学技术,分析
- 频谱分析
- 金属,重
- 白金化合物
- 放疗
- 脱氧葡萄糖
- 脱氧糖
- 过渡元素
- 放射疗法,保形
- 放疗,计算机辅助
- 氟脱氧葡萄糖F18
- 顺铂
- 1,2-二氨基环己烷柠檬酸铂 II
- 辐射
- 国会作为话题
- 标本处理
- 磁共振光谱
- 铂
- 放疗,强度调节
- 近距离放射治疗
- 3-氨基吡啶-2-辅助甲醛硫代硫酸盐
其他研究编号
- NCI-2015-01907
- NCI-2015-01907 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- HCC 15-157
- UPCI 15-157
- 15-157
- 9892 (其他标识符:CTEP)
- UM1CA186690 (美国 NIH 拨款/合同)
- 9892 (其他标识符:UPMC Hillman Cancer Center LAO)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.